If you've stopped or are planning to stop a GLP-1 medication like Ozempic or Wegovy, the honest short answer is: the research says weight regain is common and often substantial without something else in place, and a well-formulated ketogenic diet is one of the better-studied "something else" options for people managing the same appetite and blood-sugar territory these drugs work on. It isn't a drop-in replacement for the medication's mechanism, and no diet reverses the biology of stopping a GLP-1 by itself — but the eating pattern matters more, not less, once the drug is gone.
A systematic review and meta-analysis published in The BMJ in January 2026 (West et al., 37 studies, 9,341 participants) modeled weight trajectories after people stopped weight-management medication and found regain is typically fast: across all drugs studied, people regained weight at an average of about 0.4kg a month, projecting a return to baseline weight after roughly 1.7 years. For semaglutide and tirzepatide specifically — the drug classes behind Ozempic, Wegovy, and Zepbound — regain was faster still, about 0.8kg a month, with a projected return to baseline around 1.5 years. The same review found regain was consistently slower after behavioral (diet-and-exercise) weight loss than after drug-based weight loss — coverage of the review (Washington Post, US News, January 2026) put that difference at roughly four times faster for the drugs, worth reading as a reported pace comparison from a review, not a controlled head-to-head trial. A separate Cambridge-affiliated analysis on the same general question found the regain curve plateauing with patients keeping off close to a quarter of the weight they'd lost even after the fastest phase of regain — the more optimistic read of the same underlying pattern.
The consistent thread across these sources: stopping the drug without changing anything else tends to remove the main thing that was suppressing appetite, and appetite (not the diet someone happens to be on) is a large part of what determines what happens next.
This is where existing ketogenic-diet research is relevant, even though it wasn't designed to answer the GLP-1 question directly. In the Virta Health / Indiana University Health continuous-care study of a well-formulated ketogenic diet in people with type 2 diabetes, participants lost an average of roughly 12% of body weight by 12 months, with weight loss largely sustained through that first year and retention in the program holding at 83% at one year and 74% at two years. That's a different population (people with type 2 diabetes, not GLP-1 users specifically) and a different mechanism (a ketogenic diet's effect on appetite runs through ketones and stable blood sugar, not the GLP-1 pathway) — but the practical overlap is real: both approaches work partly by reducing hunger and blood-sugar swings, which is exactly the thing that tends to come back when a GLP-1 is stopped.
None of this is a claim that keto "replaces" a GLP-1 medication, and no research directly compares the two as a transition strategy — that specific study doesn't appear to exist yet. What the data supports is narrower and more honest: appetite regulation is the mechanism that matters most after stopping, and a ketogenic diet is one of the better-studied dietary approaches for managing appetite and blood sugar without medication. Anyone changing or stopping a GLP-1 medication should do it with their prescribing doctor, not based on a diet change alone.
If you're navigating this transition, Keto Coach gives you a daily plan built around protein, fat, and a handful of consistency habits — the same territory this research points to as mattering most once a GLP-1 is out of the picture.
Try Keto Coach — free, no account Get it on Google PlaySources: Weight regain after cessation of medication for weight management: systematic review and meta-analysis, The BMJ, January 2026 (West et al.) — full text via PMC; Former GLP-1 users regain lost weight after about 18 months, study says, Washington Post, Jan 8 2026; Patients regain weight rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost, University of Cambridge, 2026; Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial, Frontiers in Endocrinology, 2019 (Virta Health / Indiana University Health) — 12-month and 2-year retention/weight outcomes. These are third-party findings, summarized here — read the primary sources for full methodology before treating any specific number as settled.
Keto Coach · Sloth Lab